Current Therapies for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of the Literature
Open Access
- 1 October 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (1) , 8-23
Abstract
Aims: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical characteristics of patients with hypertrophic cardiomyopathy (HCM). Methods and results: A systematic review and meta-analysis of 41 studies identified from 1383 retrieved from PubMed, Web of Science, and Cochrane was conducted. Therapies were grouped in pharmacological, invasive and physical exercise. Pharmacological agents had no effect on functional capacity measured by VO2max (1.11 mL/kg/min; 95% CI: −0.04, 2.25, P < 0.05). Invasive septal reduction therapies increased VO2max (+3.2 mL/kg/min; 95% CI: 1.78, 4.60, P < 0.05). Structured physical exercise programmes did not report contraindications and evidenced the highest increases on functional capacity (VO2max + 4.33 mL/kg/min; 95% CI: 0.20, 8.45, P < 0.05). Patients with left ventricular outflow tract (LVOT) obstruction at rest improved their VO2max to a greater extent compared with those without resting LVOT obstruction (2.82 mL/kg/min; 95% CI: 1.97, 3.67 vs. 1.18; 95% CI: 0.62, 1.74, P < 0.05). Peak LVOT gradient was reduced with the three treatment options with the highest reduction observed for invasive therapies. Left ventricular ejection fraction was reduced in pharmacological and invasive procedures. No effect was observed after physical exercise. Symptomatic status improved with the three options and to a greater extent with invasive procedures. Conclusions: Invasive septal reduction therapies increase VO2max, improve symptomatic status, and reduce resting and peak LVOT gradient, thus might be considered in obstructive patients. Physical exercise emerges as a coadjuvant therapy, which is safe and associated with benefits on functional capacity. Pharmacological agents improve reported NYHA class, but not functional capacity.Keywords
Funding Information
- Sociedad Española de Cardiología-FEC
This publication has 61 references indexed in Scilit:
- Improvement in Left Ventricular Systolic and Diastolic Performance During Ranolazine Treatment in Patients With Stable AnginaJournal of Cardiovascular Pharmacology and Therapeutics, 2010
- Peak systolic longitudinal strain of the lateral left ventricular wall improves after septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiographyThe International Journal of Cardiovascular Imaging, 2010
- The Effects of Candesartan on Left Ventricular Hypertrophy and Function in Nonobstructive Hypertrophic CardiomyopathyThe Journal of Molecular Diagnostics, 2009
- Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditisEuropean Journal of Preventive Cardiology, 2006
- Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy: Table 1Heart, 2006
- Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-upJACC, 2000
- Predictors of exercise benefit after operative relief of left ventricular outflow obstruction by the myotomy-myectomy procedure in hypertrophic cardiomyopathyThe American Journal of Cardiology, 1992
- Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.Circulation, 1985
- Influence of verapamil therapy on left ventricular performance at rest and during exercise in hypertrophic cardiomyopathyThe American Journal of Cardiology, 1983
- Exercise performance after septal myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathyThe American Journal of Cardiology, 1979